BA-53038B is a HBV core protein allosteric modulator (CpAM) , binding to the HAP pocket and modulating HBV capsid assembly. BA-53038B has antiviral activity for hepatitis B virus (HBV) with an EC 50 value of 3.32 μM. BA-53038B can be used for the research of chronic hepatitis B In Vitro BA-53038B has antiviral activity for HBV with an EC 50 value of 3.32 μM. BA-53038B has cytotoxicity with CC 50 value of >100 μM. BA-53038B (5 μM; 48 h) induces the capsid/nucleocapsid mobility shift and reduced the amount of hypophosphorylated core protein. BA-53038B (0-20 μM; 2 or 6 days) inhibits HBV nucleocapsid assembly. BA-53038B (5 μM; 2 days) inhibits pgRNA encapsidation and consequentially reduces the amount of DNA-containing capsids and hypophosphorylated core protein. BA-53038B (2 μM; 6 h) modulates HBV capsid assembly by binding to the HAP pocket. BA-53038B has resistant effect with an EC 50 value of >10 μM on HBV capsid (HepG2 cells transiently transfected pHBV1.3/core-V124W). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: AML12HBV10 cells Concentration: 5 μM Incubation Time: 48 h Result: Reduced the amount of hypophosphorylated core protein and promoted the assembly of empty capsids with slow electrophoresis mobility. RT-PCRCell Line: AML12HBV10 and HepDES19 cells Concentration: 0-20 μM Incubation Time: 2 or 6 days Result: Inhibited HBV replication in both AML12HBV10 and HepDES19 cells. Form:Solid IC50& Target:EC 50: 3.32 μM (HBV)